[go: up one dir, main page]

PE20140375A1 - Composiciones farmaceuticas que contienen un inhibidor de dgat1 - Google Patents

Composiciones farmaceuticas que contienen un inhibidor de dgat1

Info

Publication number
PE20140375A1
PE20140375A1 PE2013000837A PE2013000837A PE20140375A1 PE 20140375 A1 PE20140375 A1 PE 20140375A1 PE 2013000837 A PE2013000837 A PE 2013000837A PE 2013000837 A PE2013000837 A PE 2013000837A PE 20140375 A1 PE20140375 A1 PE 20140375A1
Authority
PE
Peru
Prior art keywords
mixture
acid
starch
composition
pyridin
Prior art date
Application number
PE2013000837A
Other languages
English (en)
Inventor
Hong Wen
Natrajan Kumaraperumal
Richard Nause
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44908106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20140375A1 publication Critical patent/PE20140375A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA, QUE COMPRENDE: a) UN COMPUESTO DE FORMULA (I) TAL COMO EL ACIDO (4-{4-[5-(6-TRIFLUORO-METIL-PIRIDIN-3-IL-AMINO)-PIRIDIN-2-IL]-FENIL}-CICLOHEXIL)-ACETICO O UNA SAL DEL MISMO, b) UNO O MAS TENSOACTIVOS CON PROPIEDADES LUBRICANTES TALES COMO LAURIL-SULFATO DE SODIO, ACIDO ESTEARICO, ACIDO PALMITICO, ENTRE OTROS, EN UNA CANTIDAD DE 0.1% A 5% EN PESO DE LA COMPOSICION, c) UNO O MAS AGLUTINANTES SECOS CON PROPIEDADES DESINTEGRANTES TALES COMO POLIETILENGLICOLES, ALMIDON PREGELATINIZADO, QUITOSANO, ALMIDON, ENTRE OTROS, EN UNA CANTIDAD DE 5% A 15% EN PESO DE LA COMPOSICION, d) UNO O MAS RELLENOS TALES COMO UNA MEZCLA DE CELULOSA MICROCRISTALINA Y LACTOSA ANHIDRA, DONDE LA PROPORCION DE CELULOSA MICROCRIATALINA A LACTOSA ES ENTRE 1:5 Y 1:1, e) UNO O MAS DESINTEGRANTES TALES COMO CROSCARMELOSA DE SODIO, POLIVINIL-PIRROLIDONA RETICULADA, GLICOLATO DE ALMIDON DE SODIO. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION QUE COMPRENDE LOS PASOS DE: MEZCLAR EL COMPUESTO DE FORMULA (I) CON UN EXCIPIENTE, COMPACTAR CON RODILLO, MOLER LA MEZCLA, LUBRICAR LA MEZCLA RESULTANTE Y COMPRIMIR LA MEZCLA RESULTANTE EN UNA FORMA DE DOSIFICACION ORAL SOLIDA
PE2013000837A 2010-10-14 2011-10-14 Composiciones farmaceuticas que contienen un inhibidor de dgat1 PE20140375A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39310310P 2010-10-14 2010-10-14

Publications (1)

Publication Number Publication Date
PE20140375A1 true PE20140375A1 (es) 2014-03-19

Family

ID=44908106

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000837A PE20140375A1 (es) 2010-10-14 2011-10-14 Composiciones farmaceuticas que contienen un inhibidor de dgat1

Country Status (30)

Country Link
US (5) US20130190354A1 (es)
EP (1) EP2627319B1 (es)
JP (1) JP6060081B2 (es)
KR (1) KR20130100311A (es)
CN (1) CN103179957B (es)
AR (1) AR083417A1 (es)
AU (1) AU2011316003B2 (es)
BR (1) BR112013008757A2 (es)
CA (1) CA2813781C (es)
CL (1) CL2013001001A1 (es)
CO (1) CO6710915A2 (es)
DK (1) DK2627319T3 (es)
EC (1) ECSP13012755A (es)
ES (1) ES2712064T3 (es)
GT (1) GT201300096A (es)
HU (1) HUE043524T2 (es)
IL (1) IL225434A0 (es)
MA (1) MA34599B1 (es)
MX (1) MX2013004162A (es)
NZ (1) NZ608558A (es)
PE (1) PE20140375A1 (es)
PH (1) PH12013500695A1 (es)
PL (1) PL2627319T3 (es)
PT (1) PT2627319T (es)
RU (1) RU2595866C2 (es)
SG (1) SG189078A1 (es)
SI (1) SI2627319T1 (es)
TR (1) TR201902435T4 (es)
WO (1) WO2012051488A1 (es)
ZA (1) ZA201302108B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2841432A1 (en) * 2012-04-27 2015-03-04 Novartis AG Tetrahydropyran dgat1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
KR102370582B1 (ko) 2015-03-13 2022-03-04 에스페리온 테라피유틱스 인코포레이티드 Ｅｔｃ1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
TWI711464B (zh) 2015-11-19 2020-12-01 欣耀生醫股份有限公司 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017951A1 (en) 1995-11-14 1997-05-22 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19816070A1 (de) * 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
AU2006236155A1 (en) * 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
KR101219042B1 (ko) * 2005-12-06 2013-01-07 삼성디스플레이 주식회사 반투과형 액정 표시 장치
WO2007078726A2 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
TW200803850A (en) 2006-03-06 2008-01-16 Wyeth Corp Tablet formulations and processes
US20070224258A1 (en) * 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
EP2301923B1 (en) * 2006-03-31 2016-06-08 Novartis AG Pyridine derivatives as dgat inhibitors
NZ597247A (en) 2006-11-29 2013-06-28 Abbott Lab Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
KR20100017508A (ko) 2007-04-30 2010-02-16 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 1 효소의 억제제
US8283331B2 (en) * 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
EP2732818B1 (en) * 2009-03-31 2017-05-03 Ligand Pharmaceuticals Inc. A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis
WO2011123401A1 (en) * 2010-03-30 2011-10-06 Novartis Ag Uses of dgat1 inhibitors
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor

Also Published As

Publication number Publication date
CN103179957B (zh) 2016-05-18
US20150320687A1 (en) 2015-11-12
PH12013500695A1 (en) 2017-08-09
CA2813781A1 (en) 2012-04-19
WO2012051488A1 (en) 2012-04-19
SI2627319T1 (sl) 2019-04-30
GT201300096A (es) 2014-07-08
US10646446B2 (en) 2020-05-12
US20160374947A1 (en) 2016-12-29
EP2627319A1 (en) 2013-08-21
US20130190354A1 (en) 2013-07-25
ECSP13012755A (es) 2014-01-31
AU2011316003A1 (en) 2013-04-11
JP6060081B2 (ja) 2017-01-11
EP2627319B1 (en) 2018-11-21
PL2627319T3 (pl) 2019-05-31
US20200230062A1 (en) 2020-07-23
CA2813781C (en) 2018-08-07
CO6710915A2 (es) 2013-07-15
HUE043524T2 (hu) 2019-08-28
DK2627319T3 (en) 2019-03-18
CN103179957A (zh) 2013-06-26
US20180243222A1 (en) 2018-08-30
MX2013004162A (es) 2014-12-08
RU2595866C2 (ru) 2016-08-27
IL225434A0 (en) 2013-06-27
RU2013121795A (ru) 2014-11-20
BR112013008757A2 (pt) 2020-09-01
US11304907B2 (en) 2022-04-19
CL2013001001A1 (es) 2013-10-25
MA34599B1 (fr) 2013-10-02
AR083417A1 (es) 2013-02-21
NZ608558A (en) 2015-03-27
JP2013539794A (ja) 2013-10-28
TR201902435T4 (tr) 2019-03-21
KR20130100311A (ko) 2013-09-10
ES2712064T3 (es) 2019-05-09
ZA201302108B (en) 2013-11-27
PT2627319T (pt) 2019-02-27
SG189078A1 (en) 2013-05-31
AU2011316003B2 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
PE20140375A1 (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1
CL2011003072A1 (es) Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras.
MX346318B (es) Cristales.
NZ601121A (en) 5-alkynyl-pyrimidines
EP2380850A4 (en) MODIFIED SODIUM MONTMORILLONITE, PREPARATION METHOD AND USE
PE20142448A1 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
NZ727015A (en) Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CL2012003546A1 (es) Compuestos especifico acido 2-(3-(4-cianonaftalen-1-il)piridin-4-iltio)-2-metilprpanoico, en su uso fromula markush; composicion y combinacion farmaceutica que lo comprende; y uso del compuesto y de la combinacion farmaceutica en la preparacion de medicamentos para tratar enfermedades originadas por altos niveles de acido urico.
MY167791A (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
UY33614A (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
MX339252B (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
PE20120316A1 (es) Composiciones farmaceuticas solidas y procesos para su produccion
PE20151335A1 (es) Composicion farmaceutica con biodisponibilidad mejorada
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
BR112014000471A2 (pt) processo para preparo de derivados de diamida de ácido antranílico substituídos com tetrazol por meio da reação de ácidos pirazóis com ésteres antranílicos
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
AR077642A1 (es) Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
TR201902057T4 (tr) Tetrasiklin bileşikleri.
PE20110206A1 (es) Derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
PE20142399A1 (es) Compuestos de pirazol como inhibidores de sglt1
MX2010005164A (es) Derivados de bencimidazol y su uso como agonistas del receptor x de farnesoide.
ES2584556T3 (es) Composiciones novedosas que contienen carbodiimida, un procedimiento para su preparación y su uso

Legal Events

Date Code Title Description
FD Application declared void or lapsed